Biovail To Pay $24.6M Over Cardizem Marketing
Biovail Corp.'s pharmaceutical subsidiary has agreed to shell out $24.6 million to resolve criminal charges brought by the U.S. Department of Justice related to Biovail's blood pressure drug Cardizem LA....To view the full article, register now.
Already a subscriber? Click here to view full article